Abstract
Background: Although the technique of isolated pelvic perfusion dates back to the time of Creech (1959) and has been used by a variety of authors to treat unresectable neoplasms, the inherent complexity of the open procedure limited its widespread use. We simplified the technique through use of the balloon-occlusion technique for aortic and caval control. Our initial efforts used this technique for unresectable pelvic cancer, but recently we used this as preoperative therapy for advanced pelvic malignancy.
Methods: Isolated pelvic perfusion was accomplished by placement of balloon-occlusion catheters (Fogerty 8) in the aorta and inferior vena cava (IVC) at L3 vertebral body level via the common femoral artery and vein and establishing inflow and outflow catheter connections to a hemodialysis pump that generated a flow rate of 150–300 ml/min. Chemotherapy drugs were infused at times 0, 10, and 20 min. 5-Fluorouracil (5-FU; 1,500 mg/M2), cis-platinum (50–100 mg/M2), and mitomycin (15–20 mg/M2) were given by normothermic perfusion over a 45-min period. Forty isolated perfusions were carried out in 25 patients. Patients were evaluated by clinical examination, biochemical tests, computed tomography (CT) and magnetic resonance imaging (MRI) scans, and surgical exploration.
Results: Pelvic perfusion generally achieved pelvic systemic exposure ratios (area under the curve) between 5 and 10:1 for all three drugs: mean ratios were 11.4 (5-FU), 6.0 (cisplatin), and 9.0 (mitomycin). The amount of leaking to the systemic circuit ranged from 28 to 38%. Of 15 patients treated for palliation, there was one objective partial response (PR). Ten patients had symptomatic improvement of pain, two had complete pain relief (CR), and eight had partial pain relief, ranging from 3 weeks to 3 months (median, 5 weeks). Six of 10 patients with adequate carcinoembryonic antigen (CEA) follow-up data had a reduction in CEA levels (mean change, 35 units). Of 10 preoperative patients, there was one CR among five rectal cancer patients; and four of five PRs among patients with other pelvic malignancies: two PRs in patients with epidermoid cancer and one PR each in patients with endometrial cancer and metastatic anorectal melanoma.
Conclusion: Pelvic perfusion by a simplified balloon-occlusion technique provides palliation for most patients with advanced pelvic malignancy and may increase resectability and improve tumor control in patients amenable to resection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer; regional perfusion utilizing an extracorporeal circuit.Ann Surg 1959;148:616–32.
Austen WA, Monaco AP, Richardson GS, et al. Treatments of malignant pelvic tumors by extracorporeal perfusion with chemotherapeutic agents.N Engl J Med 1959;261:1037.
Watkins E Jr, Hering AC, Luna R, Adams HD. The use of intravascular balloon catheters for isolation of the pelvic bed during pump oxygenator perfusion of cancer chemotherapeutic agents.Surg Gynecol Obstet 1960;111:464–8.
Stehlin JS, Clark RL, White EC. Regional chemotherapy for cancer: experience with 116 perfusions.Ann Surg 1960;151:605.
Shingleton WW, Parker RT, Mahaley S. Abdominal perfusion for cancer chemotherapy with hypothermia and hyperthermia.Surgery 1961;50:260–5.
Lawrence W Jr, Kuehn P, Mori S. Regional perfusion of the pelvis: considerations of the leakage problem.Surgery 1961;50:248–59.
Lawrence W Jr, Clarkson B, Kim M, Clapp P, Randall HT. Regional perfusion of pelvis and abdomen by an indirect technique.Cancer 1963;16:567.
Lathrop JC, Leone LA, Soderberg CH, Colbert MP, Vargas LL. Perfusion chemotherapy for gynecological malignancy.Trans N Engl Obstet Gynecol Soc 1963;17:47–56.
Miller DG, Lawrence W. Bone marrow protection in mechlorethamine (nitrogen mustard) therapy.Arch Surg 1962;85:430–41.
Wile A, Smolin M. Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer.Arch Surg 1987;122:1321–5.
Turk PS, Belliveau JF, Darnowski JW, et al. Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.Arch Surg 1993;128:533–9.
Hafstrom L, Jonsson PE, Landberg T, et al. Intra-arterial infusion chemotherapy (5-FU) in patients with inextirpable or locally recurrent rectal cancer.Am J Surg 1979;137:757–62.
Oberfield RA. Intra-arterial infusion in tumors of the pelvis. In:Recent results in cancer research. Berlin: Springer-Verlag, 1983:15–25.
Heim ME, Eberwein S, Georgi M. Palliative therapy of pelvis tumors by intra-arterial infusion of cytotoxic drugs. In:Recent results in cancer research. Berlin: Springer-Verlag, 1983:37–40.
Patt Y, Peters RE, Chuang VP, et al. Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-FU and mitomycin.Cancer 1985;56:2175–80.
Wright KC, Wallace S, Kim EE, et al. Pulsed arterial perfusions: chemotherapeutic implications.Cancer 1986;57:1952–6.
Carlsson C, Hafstrom L, Jonsson PE, Ask A, Kallum B, Lunderquist A. Unresectable and locally recurrent rectal cancer treated with radiotherapy or bilateral internal iliac artery infusion of 5-FU.Cancer 1986;58:336–40.
Dedrich RL. Arterial drug infusion: pharmacokinetic implications: problems and pitfalls.Cancer 1986;JNCI 80:84–9.
Muchmore JH, Kramentz ET, Carter RD, Preslan JE, George WI. Treatment of abdominal malignant neoplasms using regional chemotherapy with hemofiltration.Arch Surg 1991;126:1390–6.
Forastiere AA, Belliveau JF, Goren M, Vogel WC, Posner MC, O'Leary GP. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cisdiaminedichloroplatinum (II) in head and neck cancer patients.Cancer Res 1988;48:3869–74.
DeConti RC, Toftness BR, Lange RC, Cresey WA. Clinical and pharmacological studies with cis-diaminedichloroplatinum.Cancer Res 1973;33:1310–15.
Darnowski JW, Sawyer RC, Stolfi RL, Martin DS, Lau-Cam CA. Decreased toxicity in vivo during chronic treatment for 5-fluorouracil.Cancer Chemother Pharmacol 1985;14:63–9.
MacMillan WE, Wolberg WH, Welling PG. Pharmacokinetics of fluorouracil in humans.Cancer Res 1978;38:3479–82.
den Hartigh J, van Oort WJ. High-performance liquid chromatographic determination of the antitumor agent mitomycin C in human blood plasma.Anal Chim Acta 1981;127:47–53.
Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors: presidential address.Cancer Res 1988;48:775–8.
Cavaliere R, Ciocatto BC, Giovanelli BC, et al. Selective heat sensitivity of cancer cells.Cancer 1967;20:1351–81
Nord LD, Stolfi RL, Martin DS. Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue: correlation of antitumor activity with dosage and FUra incorporation into RNA.Biochem Pharmacol 1992;43:2543–9.
Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and syustemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.J Clin Oncol 1995;13:264–73.
Lejeune FJ, Lienard D, Leyvraz S, et al. Regional chemotherapy of melanoma.Eur J Cancer 1993;294:606–12.
Hoekstra HJ, Naujocks T, Koops HS, et al. Continuous leaking monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results.Reg Cancer Treat 1992;4:301–4.
Keenan L, Turk PS, Vezeridis MP, Wanebo HJ. Isolated pelvic perfusion in a canine model: patient treatment considerations.Proc Am Soc Clin Oncol 1991;10:146.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wanebo, H.J., Chung, M.A., Levy, A.I. et al. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique. Annals of Surgical Oncology 3, 295–303 (1996). https://doi.org/10.1007/BF02306286
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02306286